NCT07262801

Brief Summary

Postpartum anxiety (PPA) affects up to 20% of mothers in the first year after delivery, with mothers often reporting both psychological and physical symptoms. Present non-pharmacological interventions are effective at improving some psychological aspects of PPA such as anxiety, depressive mood, and distress. However, current interventions are not effective in improving emotion regulation (ER), something that many with PPA experience impairment in. Current interventions also seldom target the physical aspects of anxiety, such as bodily awareness - sensing and understanding internal signals in the body (e.g., sensing a fast heartbeat). There is a link between ER and bodily awareness, however psychological interventions that target both these aspects have not been investigated in the PPA population. As a result, a mind-body intervention targeting both ER and bodily awareness is needed to offer a more holistic treatment option. The purpose of the proposed study is to test the effectiveness of a 4-week mindfulness intervention on anxiety symptoms, ER, and bodily awareness in those with PPA. We will use self-report questionnaires alongside brain imaging (functional magnetic resonance imaging; fMRI) to evaluate the effectiveness. Combining both subjective and objective measures will provide greater confidence in our findings, ensuring a more comprehensive understanding of the intervention's impact. Self-report questionnaires will be administered at enrolment, immediately post-intervention, and 4 weeks post-intervention. Brain imaging will be conducted at enrolment and immediately post-intervention. We believe this intervention will lead to improvements in anxiety symptoms, ER, and bodily awareness on the questionnaires and fMRI scans. If effective, the proposed mindfulness intervention will target a broader range of psychological and physical symptoms, and reduce the negative impact of PPA on mothers and their infants in Canada and beyond.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
4mo left

Started Dec 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress58%
Dec 2025Sep 2026

First Submitted

Initial submission to the registry

September 19, 2025

Completed
2 months until next milestone

Study Start

First participant enrolled

December 1, 2025

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 4, 2025

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Last Updated

December 4, 2025

Status Verified

December 1, 2025

Enrollment Period

9 months

First QC Date

September 19, 2025

Last Update Submit

December 1, 2025

Conditions

Keywords

postpartum anxietyanxiety disordersmothersmindfulnessmindfulness-based interventionemotion regulationinteroceptionfMRIresting state functional connectivity

Outcome Measures

Primary Outcomes (1)

  • State-Trait Inventory for Cognitive and Somatic Anxiety (STICSA)

    Administered at baseline (at enrolment), post-intervention (immediately after the 4 week intervention), and at the 3 months follow-up (3 months after intervention completion).

Secondary Outcomes (12)

  • Difficulties in Emotion Regulation Scale (DERS)

    Administered at baseline (at enrolment), post-intervention (immediately after the 4 week intervention), and at the 3 months follow-up (3 months after intervention completion).

  • Penn State Worry Questionnaire (PSWQ)

    Administered at baseline (at enrolment), post-intervention (immediately after the 4 week intervention), and at the 3 months follow-up (3 months after intervention completion).

  • Generalized Anxiety Disorder 7-Item Scale (GAD-7)

    Administered at baseline (at enrolment), post-intervention (immediately after the 4 week intervention), and at the 3 months follow-up (3 months after intervention completion).

  • Edinburgh Postnatal Depression Scale (EPDS)

    Administered at baseline (at enrolment), post-intervention (immediately after the 4 week intervention), and at the 3 months follow-up (3 months after intervention completion).

  • World Health Organization Quality of Life Scale (WHOQoL)

    Administered at baseline (at enrolment), post-intervention (immediately after the 4 week intervention), and at the 3 months follow-up (3 months after intervention completion).

  • +7 more secondary outcomes

Other Outcomes (1)

  • Resting State Functional Connectivity (fMRI)

    Completed at baseline (at enrolment) and post-intervention (immediately after the 4 week intervention), in participants randomized to the experimental group only.

Study Arms (2)

4-week mindfulness intervention

EXPERIMENTAL
Behavioral: 4-week mindfulness-based intervention

Waitlist treatment as usual control

NO INTERVENTION

Interventions

This is the first mindfulness-based intervention specifically designed for postpartum mothers and birthing parents with clinical anxiety. The protocol is adapted from Mindfulness-Based Cognitive Therapy for Depression (by J. Mark G. Williams, John D. Teasdale, and Zindel Segal), and is explicitly tailored to address anxiety disorders during the postpartum period. Most existing mindfulness-based protocols primarily target anxiety during pregnancy, are suitable for both clinical and subclinical levels of anxiety, and are commonly applied to both postpartum depression and anxiety populations.

4-week mindfulness intervention

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • mothers/birthing parents 18 years and older who are between 0-12 months postpartum
  • principal diagnosis of an anxiety disorder as per the Diagnostic Assessment Research Tool (DART; Schneider et al., 2022), with or without comorbid depression
  • no concurrent psychological treatment
  • not taking psychoactive medication or a) medications are stable in dose and type for at least 8 weeks prior to the study (as per Canadian psychiatric guidelines; McQueen et al., 2016) and b) medications remain stable throughout the study
  • fluent in English, minimal grade 8 reading level.

You may not qualify if:

  • severe depression/suicidality requiring acute intervention
  • women with psychotic or current alcohol or substance use disorders
  • suffering from severe claustrophobia
  • metallic objects in body (metal implants, pacemakers)
  • currently pregnant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton

Hamilton, Ontario, Canada

RECRUITING

Women's Health Concerns, St. Joseph's Healthcare Hamilton

Hamilton, Ontario, Canada

RECRUITING

Related Publications (1)

  • Babiy Z, Frey BN, McCabe RE, Bieling PJ, Minuzzi L, Puccinelli C, Green SM. Mindfulness-Based Intervention for Treatment of Anxiety Disorders During the Postpartum Period: A 4-Week Proof-of-Concept Randomized Controlled Trial Protocol. Brain Sci. 2026 Jan 13;16(1):88. doi: 10.3390/brainsci16010088.

MeSH Terms

Conditions

Anxiety DisordersEmotional Regulation

Condition Hierarchy (Ancestors)

Mental DisordersSelf-ControlSocial BehaviorBehavior

Study Officials

  • Sheryl M Green, Ph.D., C.Psych

    St. Joseph's Healthcare Hamilton

    PRINCIPAL INVESTIGATOR
  • Benicio N Frey, MD, PhD, FRCPC

    St. Joseph's Healthcare Hamilton

    STUDY CHAIR
  • Zoryana Babiy, M.Sc.

    McMaster University

    STUDY DIRECTOR

Central Study Contacts

Sheryl M Green, Ph.D., C.Psych

CONTACT

Zoryana Babiy, M.Sc.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr. Sheryl Green, Ph.D., C.Psych

Study Record Dates

First Submitted

September 19, 2025

First Posted

December 4, 2025

Study Start

December 1, 2025

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

September 1, 2026

Last Updated

December 4, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will share

Experimental group participants will be given the option to consent to having their de-identified REDCap questionnaires and fMRI scans data shared with the Canadian Biomarker Integration Network in Depression (CAN-BIND). CAN-BIND is a standardized research platform that supports large-scale collaboration by collecting and curating data from both healthy and clinical populations. If one chooses to provide this optional consent, their data may be used to support future ethically approved research projects. All shared data will be encrypted and de-identified to protect privacy as CAN-BIND follows strict ethical and data security standards, comparable to those at St. Joseph's Healthcare Hamilton.

Shared Documents
ICF

Locations